BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCTX BriaCell Therapeutics Corp.

Market Closed 10-04 16:00:00 EDT

0.9842

+0.0242

+2.52%

盘后0.9781

-0.0061-0.62%

19:53 EDT

High1.03	Low0.9200	Vol1.91M
Open0.9514	D1 Closing0.9600	Amplitude11.46%
Mkt Cap35.27M	Tradable Cap25.07M	Total Shares35.84M
T/O1.88M	T/O Rate7.50%	Tradable Shares25.47M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BCTX","market":"US","secType":"STK","nameCN":"BriaCell Therapeutics Corp.","latestPrice":0.9842,"timestamp":1728072000000,"preClose":0.96,"halted":0,"volume":1910761,"hourTrading":{"tag":"盘后","latestPrice":0.9781,"preClose":0.9842,"latestTime":"19:53 EDT","volume":38165,"amount":38122.6175,"timestamp":1728086030955},"delay":0,"floatShares":25468200,"shares":35838161,"eps":-0.375511,"marketStatus":"Market Closed","change":0.0242,"latestTime":"10-04 16:00:00 EDT","open":0.9514,"high":1.03,"low":0.92,"amount":1879251.67215994,"amplitude":0.114583,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.375511,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1728288000000},"marketStatusCode":7,"adr":0,"listingDate":1614142800000,"exchange":"NASDAQ","adjPreClose":0.96,"preHourTrading":{"tag":"盘前","latestPrice":0.9514,"preClose":0.96,"latestTime":"09:27 EDT","volume":24573,"amount":23545.1261538,"timestamp":1728048440762},"postHourTrading":{"tag":"盘后","latestPrice":0.9781,"preClose":0.9842,"latestTime":"19:53 EDT","volume":38165,"amount":38122.6175,"timestamp":1728086030955},"volumeRatio":0.153017,"impliedVol":3.2731,"impliedVolPercentile":0.9881},"requestUrl":"/m/hq/s/BCTX","defaultTab":"news","newsList":[{"id":"2472845699","title":"BriaCell Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2472845699","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472845699?lang=en_us&edition=fundamental","pubTime":"2024-10-03 19:12","pubTimestamp":1727953920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 03, 2024 07:12 ET (11:12 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX","LENZ"],"gpt_icon":0},{"id":"2472969310","title":"BriaCell’s Bria-IMT Regimen Shows Promise for Metastatic Breast Cancer with Brain Metastasis: A Buy Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2472969310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472969310?lang=en_us&edition=fundamental","pubTime":"2024-10-03 18:17","pubTimestamp":1727950651,"startTime":"0","endTime":"0","summary":"Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on BriaCell Therapeutics (BCT – Research Report). The associated price tar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/briacells-bria-imt-regimen-shows-promise-for-metastatic-breast-cancer-with-brain-metastasis-a-buy-recommendation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/briacells-bria-imt-regimen-shows-promise-for-metastatic-breast-cancer-with-brain-metastasis-a-buy-recommendation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCTX","BK4139"],"gpt_icon":0},{"id":"2472500799","title":"BriaCell Therapeutics Closes Offering of 5.13 Million Shares, Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2472500799","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472500799?lang=en_us&edition=fundamental","pubTime":"2024-10-03 05:46","pubTimestamp":1727905595,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics  said it closed an offering of about 5.13 million shares and warrants at a combined price of $0.975 per share and associated warrant, targeting gross proceeds of about $5 million.The warrants are for purchasing up to about 5.13 million shares, the company said late Wednesday. They have an exercise price of $0.85 per share and are immediately exercisable upon issuance for five years.BriaCell intends to use the net proceeds for working capital requirements, general corporate purposes, and advancing business objectives.Shares of the company fell 5% in after-hours activity.Price: 0.9599, Change: -0.0501, Percent Change: -4.96","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BCTX"],"gpt_icon":0},{"id":"2472507891","title":"BRIEF-Briacell Therapeutics Announces Closing Of $5 Million Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2472507891","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472507891?lang=en_us&edition=fundamental","pubTime":"2024-10-03 05:10","pubTimestamp":1727903446,"startTime":"0","endTime":"0","summary":"Briacell Therapeutics Corp   :   * BRIACELL THERAPEUTICS ANNOUNCES CLOSING OF $5 MILLION OFFERINGSource text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX","BK4139","LENZ"],"gpt_icon":0},{"id":"2472509981","title":"BriaCell Therapeutics Announces Closing of $5 Million Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2472509981","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472509981?lang=en_us&edition=fundamental","pubTime":"2024-10-03 04:05","pubTimestamp":1727899500,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, Oct.  02, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/02/2957352/0/en/BriaCell-Therapeutics-Announces-Closing-of-5-Million-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BCTX"],"gpt_icon":0},{"id":"2472585614","title":"BriaCell Therapeutics Shares Plummet After Pricing of $5 Million Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2472585614","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472585614?lang=en_us&edition=fundamental","pubTime":"2024-10-02 02:55","pubTimestamp":1727808943,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics  shares plummeted more than 40% in recent trading on Tuesday after the company priced a $5 million offering of common shares and warrants.The company said it priced the offering of about 5.12 million shares and warrants to buy roughly 5.12 million shares at $0.975 per share and associated warrant.Warrants in the offering can be exercised for $0.85 to purchase one share of the company immediately after issuance and expire after five years, BriaCell added.The company said it expects to close the offering on Wednesday and use the proceeds from the offering for working capital requirements, general corporate purposes, and advance business objectives.Price: 0.74, Change: -0.50, Percent Change: -40.08","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCTX","BK4139","LENZ"],"gpt_icon":0},{"id":"2472958351","title":"BriaCell Therapeutics Launches $5 Million Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2472958351","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472958351?lang=en_us&edition=fundamental","pubTime":"2024-10-02 02:32","pubTimestamp":1727807554,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics (TSE:BCT) has released an update. BriaCell Therapeutics Corp., a clinical-stage biotech company focused on cancer immunothera...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-launches-5-million-offering-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-launches-5-million-offering-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCTX","LENZ","BK4139"],"gpt_icon":0},{"id":"2472030020","title":"BriaCell Therapeutics Announces $5 Million Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2472030020","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472030020?lang=en_us&edition=fundamental","pubTime":"2024-10-02 02:05","pubTimestamp":1727805900,"startTime":"0","endTime":"0","summary":"Priced At-the-Market Under Nasdaq RulesPHILADELPHIA and VANCOUVER, British Columbia, Oct.  01, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/01/2956516/0/en/BriaCell-Therapeutics-Announces-5-Million-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX","LENZ","BK4139"],"gpt_icon":0},{"id":"2472332727","title":"BriaCell Reports 'Dramatic' Anti-tumor Response in Breast Cancer Patient in Phase 2 Study; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2472332727","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472332727?lang=en_us&edition=fundamental","pubTime":"2024-10-01 20:46","pubTimestamp":1727786785,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics  said Tuesday that a breast cancer patient treated in a phase 2 study of the company's Bria-IMT regimen showed a \"dramatic anti-tumor response.\"The company said treatment with its Bria-IMT regimen resulted in complete resolution of right temporal lobe brain metastasis in the patient with \"eye-bulging\" metastatic breast cancer.The patient showed an initial partial response at two months in the brain lesion without a detectable disease after eight and 11 months of treatment, the company said.The patient, who continues to receive treatment with the Bria-IMT regimen, had failed eight previous regimens including antibody-drug conjugate therapy, BriaCell said.BriaCell shares were up almost 17% in premarket activity on Tuesday.Price: 1.4499, Change: +0.21, Percent Change: +16.93","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCTX","BK4139"],"gpt_icon":0},{"id":"2472324561","title":"BriaCell reports anti-tumor response in patient treated in Phase 2 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2472324561","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472324561?lang=en_us&edition=fundamental","pubTime":"2024-10-01 19:56","pubTimestamp":1727783776,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics reports dramatic anti-tumor response including complete resolution of temporal lobe breast cancer metastasis in a patient tre...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/briacell-reports-anti-tumor-response-in-patient-treated-in-phase-2-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/briacell-reports-anti-tumor-response-in-patient-treated-in-phase-2-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCTX"],"gpt_icon":0},{"id":"2472329321","title":"BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor","url":"https://stock-news.laohu8.com/highlight/detail?id=2472329321","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472329321?lang=en_us&edition=fundamental","pubTime":"2024-10-01 19:50","pubTimestamp":1727783400,"startTime":"0","endTime":"0","summary":"Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with “Eye-Bulging” metastatic breast cancerHeavily pre-treated patient had failed 8 prior r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/01/2956018/0/en/BriaCell-Reports-100-Resolution-of-Brain-Metastasis-in-Breast-Cancer-Patient-with-Eye-Bulging-Tumor.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBC","BCTX","BK4231","BK4080","BK4086","BK4139","ADC"],"gpt_icon":0},{"id":"2470346890","title":"What Makes BRIACELL THERAP (BCTX) a New Strong Buy Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2470346890","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470346890?lang=en_us&edition=fundamental","pubTime":"2024-09-28 00:00","pubTimestamp":1727452811,"startTime":"0","endTime":"0","summary":"BRIACELL THERAP  could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 . This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.As such, the Zacks rating upgrade for BRIACELL THERAP is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.This company i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wbCMwMtKIoXj_iQA0ego4g--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wbCMwMtKIoXj_iQA0ego4g--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/makes-briacell-therap-bctx-strong-160011424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BCTX","BCTXW"],"gpt_icon":0},{"id":"2468852753","title":"Briacell Therapeutics Corp : H.c. Wainwright Cuts Target Price to $15 From $18","url":"https://stock-news.laohu8.com/highlight/detail?id=2468852753","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468852753?lang=en_us&edition=fundamental","pubTime":"2024-09-19 19:02","pubTimestamp":1726743746,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240919:nFWN3L10AX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTX","BK4139"],"gpt_icon":0},{"id":"2468836185","title":"BriaCell Says FDA Greenlit Expanded Access Policy for Metastatic Breast Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2468836185","media":"MT Newswires Live","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468836185?lang=en_us&edition=fundamental","pubTime":"2024-09-18 20:20","pubTimestamp":1726662058,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics  said Wednesday that the US Food and Drug Administration authorized an expanded access policy allowing metastatic breast cancer patients to access the company's Bria-IMT regimen beyond the scope of an ongoing pivotal phase 3 trial.The FDA requires BriaCell to have an EAP as a condition to granting its fast track designation, the company said.Shares of the company were up more than 7% in recent Wednesday premarket activity.Price: 0.5034, Change: +0.03, Percent Change: +7.11","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCTX","BK4139"],"gpt_icon":1},{"id":"2468583593","title":"BriaCell Offers New Hope for Breast Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2468583593","media":"TIPRANKS","labels":["Product Release","Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468583593?lang=en_us&edition=fundamental","pubTime":"2024-09-18 20:08","pubTimestamp":1726661293,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics (TSE:BCT) has released an update. BriaCell Therapeutics has announced that the FDA has authorized an Expanded Access Policy a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/briacell-offers-new-hope-for-breast-cancer-patients?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/briacell-offers-new-hope-for-breast-cancer-patients?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4211","HOPE","BCTX"],"gpt_icon":0},{"id":"2468300666","title":"BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2468300666","media":"GlobeNewswire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468300666?lang=en_us&edition=fundamental","pubTime":"2024-09-18 19:50","pubTimestamp":1726660200,"startTime":"0","endTime":"0","summary":"FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel treatmentsExpanded access policy will provide potential lifesaving Bria-IMT to those can","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/18/2948125/0/en/BriaCell-Announces-FDA-Authorized-Expanded-Access-Policy-for-Metastatic-Breast-Cancer-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4086","MBC","BK4139","BCTX"],"gpt_icon":1},{"id":"2467372077","title":"BRIEF-BriaCell Therapeutics Announces Closing Of $8.5 Million Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2467372077","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467372077?lang=en_us&edition=fundamental","pubTime":"2024-09-13 05:53","pubTimestamp":1726178001,"startTime":"0","endTime":"0","summary":"Sept 12 (Reuters) - Briacell Therapeutics Corp   :   * BRIACELL THERAPEUTICS ANNOUNCES CLOSING OF $8.5 MILLION OFFERINGSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCTX","LENZ"],"gpt_icon":1},{"id":"2467352077","title":"BriaCell Therapeutics Announces Closing of $8.5 Million Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2467352077","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467352077?lang=en_us&edition=fundamental","pubTime":"2024-09-13 04:05","pubTimestamp":1726171500,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, Sept.  12, 2024  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechn","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/12/2945578/0/en/BriaCell-Therapeutics-Announces-Closing-of-8-5-Million-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BCTX"],"gpt_icon":1},{"id":"2466169259","title":"BriaCell Therapeutics Announces US$8.5 Million Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2466169259","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466169259?lang=en_us&edition=fundamental","pubTime":"2024-09-12 02:08","pubTimestamp":1726078117,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics  on Wednesday announced the pricing of a best-efforts offering of 12.33-million shares, or pre-funded warrants, to raise US$8.5 million.The offering, priced at-the-market under Nasdaq rules, consists of a share or pre-funded warrant being sold at US$0.69 per share, inclusive of the pre-funded warrant exercise price.The offering is expected to close on Thursday, September 12.Proceeds will be used for working capital, general corporate purposes, and the advancement of business objectives.BriaCell earlier today announced longer overall survival rate in its Phase 2 study of Bria-IMT with an immune check point inhibitor  in late stage metastatic breast cancer.The patients reported median overall survival of 15.6 months  compared with 6.7-9.3 months for similar patients reported in the literature. The latest data are also an improvement over BriaCell's 13.4 months median overall survival that was reported last December. These patients are being treated with the same Bri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-therapeutics-announces-us-8-180837848.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCTXW","BK4139","LENZ","BCTX","CPI"],"gpt_icon":1},{"id":"2466534512","title":"Sector Update: Health Care Stocks Softer in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2466534512","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466534512?lang=en_us&edition=fundamental","pubTime":"2024-09-12 02:04","pubTimestamp":1726077856,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["IBB","FDN","BK4139","XLV","APDN","BK4583","BK4581","BK4109","BCTX","BK4585","BK4121","NYSE","DNA","BK4550","BK4588","RENB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://briacell.com","stockEarnings":[{"period":"1week","weight":0.1168},{"period":"1month","weight":0.3611},{"period":"3month","weight":-0.0255},{"period":"6month","weight":-0.6382},{"period":"1year","weight":-0.8332},{"period":"ytd","weight":-0.8318}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":0.04},{"period":"3month","weight":0.0331},{"period":"6month","weight":0.1052},{"period":"1year","weight":0.3498},{"period":"ytd","weight":0.2055}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.059743},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.002131},{"month":3,"riseRate":0.75,"avgChangeRate":0.085777},{"month":4,"riseRate":0,"avgChangeRate":-0.150063},{"month":5,"riseRate":0,"avgChangeRate":-0.204537},{"month":6,"riseRate":0.75,"avgChangeRate":0.134713},{"month":7,"riseRate":0.5,"avgChangeRate":-0.054561},{"month":8,"riseRate":1,"avgChangeRate":0.163345},{"month":9,"riseRate":0.5,"avgChangeRate":0.089973},{"month":10,"riseRate":0,"avgChangeRate":-0.14154},{"month":11,"riseRate":0.666667,"avgChangeRate":0.152935},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.079632}],"exchange":"NASDAQ","name":"BriaCell Therapeutics Corp.","nameEN":"BriaCell Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BriaCell Therapeutics Corp.(BCTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BriaCell Therapeutics Corp.,BCTX,BriaCell Therapeutics Corp.股票,BriaCell Therapeutics Corp.股票老虎,BriaCell Therapeutics Corp.股票老虎国际,BriaCell Therapeutics Corp.行情,BriaCell Therapeutics Corp.股票行情,BriaCell Therapeutics Corp.股价,BriaCell Therapeutics Corp.股市,BriaCell Therapeutics Corp.股票价格,BriaCell Therapeutics Corp.股票交易,BriaCell Therapeutics Corp.股票购买,BriaCell Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BriaCell Therapeutics Corp.(BCTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction